ProCE Banner Activity

Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors

Clinical Thought

In this commentary, expert faculty discuss best practices for integrating CDK4/6 inhibitors into care for patients with HR+/HER2- breast cancer, including adverse event management and strategies for promoting adherence.

Released: May 31, 2022

Expiration: May 30, 2023

Begin Activity

Share

Faculty

Julia LaBarbera

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California

Acknowledgement

This activity is supported by an educational grant from Lilly.

Supporters

Lilly

Target Audience

NPs and PAs in oncology

Disclosure

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics, MJH Life Sciences.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Format

Clinical Thought

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.